{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:38:55Z","timestamp":1794278335780,"version":"4.9.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Karolinska Institute Region Stockholm","id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the occurrence and relative risks of first-ever-incident non-cutaneous cancer overall and for 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b\/tsDMARDs), by time since treatment start, attained age, and duration of active treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an observational nationwide and population-based cohort study of patients with RA (n\u2009=\u200969 308), treated with TNF inhibitors (TNFi; adalimumab, certolizumab, etanercept, golimumab, infliximab) or other b\/tsDMARDs (abatacept, rituximab, baricitinib, tofacitinib and tocilizumab) compared with RA patients not treated with b\/tsDMARDs, and matched general population referents (n\u2009=\u2009109 532), 2001\u20132018. The study was based on prospectively collected data from the Swedish Rheumatology Quality Register and from other registers, linked to the national Swedish Cancer Register. Incidence rates and hazard ratios were estimated via Cox regression adjusted for co-morbidities and other health characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Based on 8633 incident cancers among RA patients, the overall relative risk of cancer with TNFi [hazard ratio (HR)\u2009=\u20091.0] was neither increased nor did it change with time since treatment start, duration of active treatment, or attained age, when compared with b\/tsDMARD-na\u00efve RA. For other b\/tsDMARDs, we noted no consistent signal of increased overall risks (HRs ranged from 1.0 to 1.2), but there were statistically significant estimates above 1 for abatacept with 2\u20135\u2009years of active treatment, for older age groups, and between several of the bDMARDs and urinary tract cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TNFis, as used long term in clinical practice against RA, are not linked to increased risks for cancer overall. For other b\/tsDMARDs, and for site-specific risks, our results are generally reassuring but contain signals that call for replication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab570","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T15:13:23Z","timestamp":1627485203000},"page":"1810-1818","source":"Crossref","is-referenced-by-count":80,"title":["Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9764-6435","authenticated-orcid":false,"given":"Viking","family":"Huss","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"},{"name":"Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Bower","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-5536","authenticated-orcid":false,"given":"Hjalmar","family":"Wadstr\u00f6m","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"},{"name":"Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ARTIS group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-Marie","family":"Ahlenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baecklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Feltelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Forsblad-d\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alf","family":"Kastbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Klareskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"2022050522153242500_keab570-B1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2022050522153242500_keab570-B2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1185\/03007995.2015.1011778","article-title":"Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk","volume":"31","author":"Lebrec","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2022050522153242500_keab570-B3","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"2022050522153242500_keab570-B4","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"Jama"},{"key":"2022050522153242500_keab570-B5","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incidence or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2022050522153242500_keab570-B6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"key":"2022050522153242500_keab570-B7","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022050522153242500_keab570-B8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides \u2013 a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022050522153242500_keab570-B9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2022050522153242500_keab570-B10","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti\u2013tumor necrosis factor \u03b1 therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022050522153242500_keab570-B11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022050522153242500_keab570-B12","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"2022050522153242500_keab570-B13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jbspin.2010.11.012","article-title":"Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort","volume":"78","author":"Slimani","year":"2011","journal-title":"Joint Bone Spine"},{"key":"2022050522153242500_keab570-B14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.semarthrit.2019.01.009","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of serious infection: a population-based cohort study","volume":"48","author":"Montastruc","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2022050522153242500_keab570-B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rdc.2016.09.008","article-title":"Malignancy and Janus Kinase inhibition","volume":"43","author":"Sivaraman","year":"2017","journal-title":"Rheum Dis Clin N Am"},{"key":"2022050522153242500_keab570-B16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"2022050522153242500_keab570-B17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022050522153242500_keab570-B18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022050522153242500_keab570-B19","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522153242500_keab570-B20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022050522153242500_keab570-B21","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022050522153242500_keab570-B22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab570\/40434893\/keab570.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/1810\/43562075\/keab570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/1810\/43562075\/keab570.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T18:23:13Z","timestamp":1651774993000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/5\/1810\/6330769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,7,29]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab570","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,7,29]]}}}